| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel HF Günthard, MS Saag, CA Benson, C Del Rio, JJ Eron, JE Gallant, ... Jama 316 (2), 191-210, 2016 | 856 | 2016 |
| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel MS Saag, CA Benson, RT Gandhi, JF Hoy, RJ Landovitz, MJ Mugavero, ... Jama 320 (4), 379-396, 2018 | 713 | 2018 |
| Cabotegravir for HIV prevention in cisgender men and transgender women RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ... New England Journal of Medicine 385 (7), 595-608, 2021 | 521 | 2021 |
| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA Panel MS Saag, RT Gandhi, JF Hoy, RJ Landovitz, MA Thompson, PE Sax, ... Jama 324 (16), 1651-1669, 2020 | 471 | 2020 |
| Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California RJ Landovitz, CH Tseng, M Weissman, M Haymer, B Mendenhall, ... Journal of Urban Health 90, 729-739, 2013 | 381 | 2013 |
| An HIV preexposure prophylaxis demonstration project and safety study for young MSM SG Hosek, B Rudy, R Landovitz, B Kapogiannis, G Siberry, B Rutledge, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 74 (1), 21-29, 2017 | 309 | 2017 |
| Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor–sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized … JL Lennox, RJ Landovitz, HJ Ribaudo, I Ofotokun, LH Na, C Godfrey, ... Annals of internal medicine 161 (7), 461-471, 2014 | 309 | 2014 |
| Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel RT Gandhi, R Bedimo, JF Hoy, RJ Landovitz, DM Smith, EF Eaton, ... Jama 329 (1), 63-84, 2023 | 270 | 2023 |
| Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study RA Brooks, RJ Landovitz, RL Kaplan, E Lieber, SJ Lee, TW Barkley AIDS patient care and STDs 26 (2), 87-94, 2012 | 254 | 2012 |
| Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States SG Hosek, RJ Landovitz, B Kapogiannis, GK Siberry, B Rudy, B Rutledge, ... JAMA pediatrics 171 (11), 1063-1071, 2017 | 217 | 2017 |
| Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial RJ Landovitz, S Li, B Grinsztejn, H Dawood, AY Liu, M Magnus, ... PLoS medicine 15 (11), e1002690, 2018 | 174 | 2018 |
| Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships RA Brooks, RL Kaplan, E Lieber, RJ Landovitz, SJ Lee, AA Leibowitz AIDS care 23 (9), 1136-1145, 2011 | 167 | 2011 |
| Postexposure prophylaxis for HIV infection RJ Landovitz, JS Currier New England Journal of Medicine 361 (18), 1768-1775, 2009 | 138 | 2009 |
| Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial RJ Landovitz, S Li, JJ Eron, B Grinsztejn, H Dawood, AY Liu, M Magnus, ... The lancet HIV 7 (7), e472-e481, 2020 | 130 | 2020 |
| The promise and pitfalls of long-acting injectable agents for HIV prevention RJ Landovitz, R Kofron, M McCauley Current Opinion in HIV and AIDS 11 (1), 122-128, 2016 | 130 | 2016 |
| COVID-19 vaccine decision-making factors in racial and ethnic minority communities in Los Angeles, California SL Carson, A Casillas, Y Castellon-Lopez, LN Mansfield, J Barron, ... JAMA network open 4 (9), e2127582-e2127582, 2021 | 123 | 2021 |
| Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial RV Barnabas, ER Brown, A Bershteyn, HC Stankiewicz Karita, ... Annals of internal medicine 174 (3), 344-352, 2021 | 114 | 2021 |
| Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline LE Coelho, TS Torres, VG Veloso, RJ Landovitz, B Grinsztejn The Lancet HIV 6 (11), e788-e799, 2019 | 104 | 2019 |
| Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257 I Ofotokun, LH Na, RJ Landovitz, HJ Ribaudo, GA McComsey, C Godfrey, ... Clinical Infectious Diseases 60 (12), 1842-1851, 2015 | 98 | 2015 |
| Online social networking, sexual risk and protective behaviors: Considerations for clinicians and researchers IW Holloway, S Dunlap, HE Del Pino, K Hermanstyne, C Pulsipher, ... Current addiction reports 1, 220-228, 2014 | 94 | 2014 |
